Philippe Pierre Goupit
Chairman at Tollys
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Patrick Kron | M | 70 | 10 years | |
| Chris Buyse | M | 59 | 7 years | |
| Annick Schwebig | M | 73 | 7 years | |
| Jacques-François Martin | M | 78 |
Tollys
 Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
| Fabienne Lecorvaisier | F | 61 | 11 years | |
| Dominique Rigal | M | - |
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
| Dino Dina | M | 77 |
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
| Olivier Antoine M. Charmeil | M | 59 | 18 years | |
| Chahra Khaoua Epouse Louafi | F | 53 |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | 8 years |
| Vincent Charlon | M | - |
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
| Céline Saint Olive Baque | M | - |
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Serge Weinberg | M | 73 | - | |
| Jean-René Fourtou | M | 84 | - | |
| Marc Cluzel | M | 69 | 19 years | |
| Jean Zetlaoui | M | - | 19 years | |
| Daniel Schirlin | M | - | - | |
| Thierry Vernier | M | - | - | |
| Ji Zhang | M | - | - | |
| Philippe Peyre | M | 73 | - | |
| Bonnie Bassler | M | 61 | 2 years | |
| Catherine Moukheibir | F | 64 |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | 5 years |
| Suet-Fern Lee | F | 66 | 9 years | |
| Matthew Ros | M | 57 | 5 years | |
| Claudie Haigneré | M | 67 | 12 years | |
| Dominique Carouge | M | - | - | |
| Arthur Charles V. Wellesley | M | 78 | 12 years | |
| Robert Castaigne | M | 78 | 18 years | |
| Christian Chavy | M | 75 |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | 1 years |
| Klaus Pohle | M | 86 | 12 years | |
| Mishima Gerhart | F | - | 6 years | |
| Muriel Bardet | F | - | 16 years | |
| Jürgen Dormann | M | 84 | - | |
| Gérard van Kemmel | M | 84 | - | |
| Thierry Desmarest | M | 78 | 14 years | |
| Uwe Bicker | M | 78 | - | |
| Carole Piwnica | F | 66 | 12 years | |
| Jorge Insuasty | M | - | - | |
| Christopher Viehbacher | M | 64 | 6 years | |
| Bernard Davitian | M | 64 |
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | 4 years |
| Rima Bawarsh Nassar | M | 70 | 5 years | |
| Alain Herrera | M | 74 | 10 years | |
| Heraldo Carvalho Marchezini | M | - | 4 years | |
| Léopold Bertea | M | 60 | 6 years | |
| Nathalie Therrien | F | 56 | 3 years | |
| David Loew | M | 57 | 7 years | |
| Gary Nabel | M | 70 | 8 years | |
| Riccardo Perfetti | M | 64 | 11 years | |
| Marie-Claire Simone Daveu | F | 53 | - | |
| Andrew Plump | M | 58 | - | |
| Nitza Thomasson-Perret | M | 51 | - | |
| Stefan Oelrich | M | 55 | 7 years | |
| Claire Massiot-Jouault | F | 62 | 5 years | |
| Philippe Motté | M | 64 |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | 1 years |
| Amit Hasija | M | 51 | 5 years | |
| Gérard Le Fur | M | 73 | 22 years | |
| Robin E. Harkness | M | - | - | |
| Joanne Lager | M | 52 | 10 years | |
| Essy Mozaffari | M | - | - | |
| Dario Eklund | M | 56 | 2 years | |
| Christian Antoni | M | 62 | - | |
| John Felitti | M | 54 | 13 years | |
| Dennis Urbaniak | M | - | 3 years | |
| Emmanuel Dulac | M | 55 | 9 years | |
| Robert Sebbag | M | 73 | 10 years | |
| Pierre Gibert | M | - | 2 years | |
| Robert DeBerardine | M | - | - | |
| Jean-Sébastien Cleiftie | M | 50 | 6 years | |
| Roberto Pucci | M | 60 | 9 years | |
| Catherine Bréchignac | M | 77 | - | |
| David Meeker | M | 69 | 4 years | |
| Carsten Hellmann | M | 60 | 3 years | |
| Wayne Pisano | M | 69 | - | |
| Laurent Attal | M | 66 | 9 years | |
| Thomas DesRosier | M | 69 | 2 years | |
| Jean-Claude Leroy | M | - | - | |
| Christian Mulliez | M | 63 | 15 years | |
| Lindsay Owen-Jones | M | 78 | 13 years | |
| Gunter Thielen | M | 81 | 1 years | |
| Stanislas B. H. E. Weymuller | M | 76 | - | |
| Igor Landau | M | 78 | 11 years | |
| Janet Vergis | F | 59 |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | 5 years |
| Frédéric Revah | M | 62 | 6 years | |
| Karen Linehan | F | 65 | 25 years | |
| Thierry Bourquin | M | - | - | |
| Paul Herbert Chew | M | 72 | 3 years | |
| François Beloeuvre | M | - | - | |
| Olivier Jacquesson | M | - | - | |
| Laure Thibaud | F | - | - | |
| Bruno Ménard | M | - | - | |
| David-Alexandre Gros | M | 51 | 4 years | |
| Jez Moulding | M | - | - | |
| Pascale Witz | F | 57 | 3 years | |
| Jean-Pierre Lehner | M | - | 4 years | |
| Jean-Luc Lowinski | M | 60 | - | |
| Christophe Francois Gourlet | M | - | - | |
| Anne Beal | M | 62 | - | |
| Franck Hamalian | M | - | - | |
| Pierre Chancel | M | 67 | - | |
| George Parker | M | - | 2 years | |
| Jean-Philippe Collin | M | 67 | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Philippe Pierre Goupit
- Personal Network
